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about which outcome is affected (the Canadian study did not 
find an association between maternal work with leather and 
prematurity,12 but mothers employed as leather workers in 
Leicestershire, UK, were twice as likely as other manual 
workers to have a perinatal death11). In contrast to maternal 
occupational exposures, there is little to suggest that paternal 
exposures are associated with a substantial risk of 
prematurity. The only exception is perhaps for the children 
of male ceramic workers, but our finding should be treated 
with caution, since we have found no other corroborating 
reports.
The three adverse outcomes studied here are not 
independent measures of prematurity. Low birth weight and 
preterm delivery are highly correlated, and RR estimates for 
each are often similar in the same occupational group. 
Small-for-gestational age is a composite measure of 
birth weight and gestational age. It is noteworthy that the 
risk of this adverse outcome hardly varied between 
occupational groups; this suggests that occupational factors 
act by increasing the risk of preterm delivery, rather than by 
slowing intrauterine growth.
In conclusion, these data indicate that neither maternal 
nor paternal occupational exposures have strong effects on 
the risk of prematurity. Where there is evidence of adverse 
effects, they are associated with maternal rather than with 
paternal exposures.
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HYPOTHESIS
Adverse reactions to 
co-trimoxazole in HIV infection
A n d r e  J. A. M . v a n  d e r  V e n  
P e t e r  P. K o o p m a n s  T o m  B. V r e e  
J o s  W . M . v a n  d e r  M e e r
The origin of the increased frequency of side-effects 
to co-trimoxazole in HIV-positive patients is 
unknown. Data on plasma concentrations of the 
parent compounds are inconclusive. Evidence 
points to the hydroxylamine derivatives of 
sulphamethoxazole as the reactive metabolites that 
cause adverse reactions to co-trimoxazole. HIV- 
positive individuals have a systemic glutathione 
deficiency, and therefore a reduced capacity to 
scavenge such metabolites. This process would lead 
to an increased exposure to toxic intermediates and 
would explain the high frequency of adverse 
reactions to co-trimoxazole in these patients.
Lancet 1991; 338: 431-33.
Pneumocystis carinii pneumonia is an important 
opportunistic infection in patients with the acquired 
immunodeficiency syndrome (AIDS). Treatment with a 
high dose of co-trimoxazole—20 mg/kg trimethoprim 
(TMP) and 100 mg/kg sulphamethoxazole (SMX)—is 
recommended. The frequency of adverse reactions to 
co-trimoxazole in patients with AIDS (40-80%) is much 
higher compared with other patients, even those who are 
immunodeficient.1'8 The explanation for this increased 
side-effect profile is unknown.
Trimethoprim and possible side-effects
Controversy exists as to whether side-effects depend on 
serum concentrations of TM P.4-7 Serum concentrations 
above 25 mg/1 in patients with AIDS may be associated with 
leucopenia, and dose reduction to maintain serum 
concentrations between 5 and 8 mg/1 may reduce the risk of 
bone marrow suppression while preserving antimicrobial 
efficacy.7 Other studies have shown that the serum 
concentration of TM P was 48% higher in patients treated 
with TM P and dapsone compared with patients treated 
with TM P and SMX, whereas adverse events were more 
common in the TM P/SM X  group.4,8
TM P inhibits dihydrofolate reductase and can cause 
megaloblastic anaemia and neutropenia in patients whose 
folate stores are deficient. In some patients, megaloblastic 
changes in bone marrow have been found despite normal 
serum folate concentrations.6 However, other studies have
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either failed to find megaloblastic changes or report no 
therapeutic benefit with folinic acid.1-2 A different 
mechanism that explains the haematological changes has 
been described. Antibodies to polymorphonuclear cells have 
been found in untreated HIV-infected patients and were 
shown to increase according to the degree of neutropenia in 
co-trimoxazole-treated AIDS patients.9 Therefore no 
convincing data show that TM P is the main cause of the 
side-effects in such patients, although a contributory role 
cannot be excluded.
Su/phamethoxazo/e and possible side-effects
The relevance of serum concentrations of SMX to the 
development of adverse reactions in AIDS patients is also 
controversial.3-5 Some workers do not believe that high 
serum SMX concentrations are a contributory factor,3 
whereas other groups do share this belief.5 Other 
mechanisms may be more important, such as formation of 
sulphonamide metabolites.
Sulphamethoxazole is metabolised (figure) by N- 
acetyltransferase (50-70%) to N4-acetylsulphamethoxazole 
(N4-SMX), and by the cytochrome-P450 system (10-15%) 
to 5-hydroxysulphamethoxazole (SM X-50H). SMX can 
also be oxidised on the N4 position to form a hydroxylamine 
derivative.10-13 The rate of production of this reactive 
intermediate may be influenced by the rate of acetylation of 
the parent compound,12 which suggests that acetylator 
status is important. Inherited differences in the rate of 
production of this reactive metabolite may also contribute to 
this process.13 The hydroxylamine metabolite is an 
electrophilic, reactive compound that can bind covalently to 
macroglobulins; it must be scavenged by the oxidant- 
buffering capacity of glutathione before it is excreted in the 
urine. In-vitro studies show that hydroxylamine metabolites 
lead to increased cytotoxicity towards lymphocytes of 
patients with a clinical history of sulphonamide 
hypersensitivity compared with control lymphocytes of 
non-allergic individuals.10-13 The cytotoxicity of these 
hydroxylamine derivatives diminished after coincubation 
with glutathione or N-acetylcysteine.10,12 Hydroxylamine 
derivatives may have a direct cytotoxic action because of the 
ability of these electrophilic species to bind to 
macroglobulins. This process may lead to formation of 
haptens that could stimulate an immune response. 
Scavenging of these hydroxylamine derivatives by 
glutathione might be crucial for prevention of covalent 
binding and toxicity. Hypersensitivity may be due to 
increased production of a reactive metabolite together with 
the relative inability of tissues to detoxify such a substance.14
Glutathione concentrations in HIV-positive individuals
Glutathione is an important antioxidant. In patients with 
AIDS, as well as in symptom-free HIV-positive 
individuals, glutathione concentrations in both serum and 
bronchoalveolar lavage fluid were significantly reduced.1516 
The mechanisms that lead to this systemic glutathione 
deficiency are unknown. Decreased glutathione synthesis, 
increased catabolism, and increased use could all be 
involved.16 The reactive metabolites of sulphonamides are 
scavenged by glutathione.12 The formation and scavenging 
of hydroxylamine derivatives takes place throughout the 
body, since both the cytochrome-P450 system and 
glutathione are widely distributed.
Hypothesis
The hydroxylamine derivatives of sulphamethoxazole are 
the reactive metabolites that cause adverse reactions to
CHjC-NH
N4-acetylsulphamethoxazole
NH2-(0)-R ^ --- '•NH2 - ( § ) - R-0H
Sulphamethoxazole 5-hydroxysulphamethoxazole
HO-NH cT-nhhQ hr+h*
Hydroxylamine metabolite Reactive metabolite
Sulphamethoxazole metabolism.
co-trimoxazole. HIV-positive individuals have a systemic 
glutathione deficiency, and therefore a reduced capacity to 
scavenge such reactive metabolites. This process would lead 
to an increased exposure to toxic intermediates and would 
explain the high frequency of adverse reactions to co- 
trimoxazole in these patients. When adverse reactions to 
co-trimoxazole do occur, dose reduction will often diminish 
the severity of these events. This observation suggests a 
dose-related toxicity rather than true hypersensitivity but, as 
discussed above, measurements of serum concentrations of 
the parent compounds TM P and SMX do not clearly 
support this relation. Toxicity may be caused by the 
metabolite rather than the parent compound. Inherited 
differences in the rate of production of these (toxic) 
metabolites, like acetylator status,13 could add to an 
individual’s susceptibility to adverse events and would 
explain the lower frequency of side-effects reported in 
African, Haitian, and black American patients with 
AIDS.17,18 The observation that side-effects occur after 8 to 
12 days might suggest a role for a metabolite, either by slow 
accumulation or by an immune response that the metabolite 
could initiate.
Although our hypothesis seems attractive because the 
formation of hydroxylamine derivatives is theoretically 
likely, detection of these reactive species by methods such as 
high-performance liquid chromatography, has never been 
reported. Furthermore, hydroxylamine derivatives can have 
either a direct toxic effect or function as a hapten, but which 
of the side-effects of sulphamethoxazole in HIV-positive 
patients are toxic or immunological remains unclear. In 
addition, a possible contributory role of TM P cannot be 
excluded. Like sulphamethoxazole, TM P has a para-amino 
group that could be oxidised to form hydroxylamines. 
Glutathione synthesis requires sulphur-containing 
aminoacids and their metabolism is linked to folic acid and 
cobalamin; TM P could influence this synthetic pathway.19
There are two ways to substantiate this hypothesis. 
Firstly, N-acetylcysteine could be added to co-trimoxazole 
treatment. N-acetylcysteine replenishes cysteine and 
sustains glutathione synthesis when demand for glutathione 
is increased.20 Secondly, by selecting sulphonamides that are 
not easily N-hydroxylated, the generation of reactive 
metabolites might be prevented. With these modifications 
of the standard regimens of prophylaxis against 
Pneumocystis carinii pneumonia, side-effects could be 
largely eliminated.
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Operative Arthroscopy
Edited by John B. McGinty. New York: Raven. 1990. Pp 798.
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Arthroscopic surgery is now an important orthopaedic 
subspecialty and for some surgeons represents a large part of 
their routine workload. Improved instrumentation, such as 
powered arthroscopy, has led to striking advances in patient 
management. Gone are the days of admissions to hospital for 
open arthrotomy; instead a patient is admitted, his or her 
tom meniscus removed, discharged on the same day, and is 
soon back to full activity. Thomas Annandale, an 
Edinburgh professor of clinical surgery who was the first 
person to open a knee joint to remove a meniscus, 
undoubtedly would have been impressed.
This very comprehensive book, edited by an 
acknowledged expert in the discipline, brings together many 
authorities who have contributed to these advances. It not 
only includes details about operative arthroscopic 
techniques but also how to select and use the correct 
instrument. In the knee, for example, topics such as 
treatment of synovial plica, always rather a mystery to many 
surgeons trained in open arthrotomy, are clearly described. 
There are sections on use of the arthroscope in the 
shoulder—where is is now possible to repair the rotator cuff, 
let alone deal with impingement syndrome—and on 
arthroscopic surgery of the wrist and the elbow. For real 
afficianados there is even a section on how to examine the 
ankle joint and achieve tibiotalar arthrodesis. Another 
section on the temporomandibular joint clearly indicates 
that no area is safe from the inspecting scope, and probable 
improvement in patient care. There are excellent and well 
reproduced illustrations throughout and many background 
references.
Few prospective clinical trials are yet available on the use 
of arthroscopic surgery; hopefully they will come, but they 
cannot really be matched against open surgery in this day 
and age. But does simple observation, description and 
resection of an abnormality represent care? In our eagerness
toxicity of hydroxylaminc metabolites of sulfonamides. J  Pharmacol 
Exp Ther 1985;244: 724-28.
11. Rieder MJ, Uetrecht J, Shear N H , et al. Diagnosis of sulfonamide
hypersensitivity reactions by in vitro rechallenge with hydroxylamine 
metabolites. Arm Int Med 1989; 110: 286-89.
12. Shear N H , Spielberg SP. In vitro evaluation of a toxic metabolite of
sulfadiazine. C anJ Physiol Pharmacol 1985; 63: 1370-72.
13. Shear NH, Spielberg SP, Grant DM , Tang BK, Kalow W. Differences
in metabolism of sulfonamides predisposing to idiosyncratic toxicity. 
Ann Int Med 1986; 105: 179-84.
14. Editorial. Hypersensitivity to sulfonamides: a clue? Lancet 1986; ii:
958-59.
15. Eck HP, Gmünder H, Hartman M, et al. Low concentrations of
acid-soluble thiol (cysteine) in the blood plasma of HIV-1 infected 
patients. Biol Chem Hoppe Seyler 1989; 370: 101-08.
16. Buhl R, Jaife HA, Holroyd KJ, et al. Systemic glutathione deficiency in
symptom-free HIV-seropositive individuals. Lancet 1989; ii: 1294-98.
17. Colebunders R, Izaley L, Bila K, et al. Cutaneous reactions to
trimethoprim-sulfamethoxazole in African patients with the acquired 
immunodeficiency syndrome. Ami Int Med 1987; 107: 599-600.
18. Dehovitz JA, Johnson W D, Pape JW. Cutaneous reactions to
trimethoprim-sulfamethoxazole in Haitians. Ann Int Med 1985; 103: 
479-80.
19. Refsum H, Ueland PM. Clinical significance of pharmacological
modulation of homocysteine metabolism. T IP S  1990; 11: 411-16.
20. Burgunder JM , Varriale A, Lauterburg BH. Effect of N-acetylcysteine
on plasma cysteine and glutathione following paracetamol 
administration. E urJ Clin Pharmacol 1989; 36: 127-31.
to provide symptomatic relief we must not overlook the 
underlying cause or causes of the abnormalities that we 
resea: for example, is a medial parapatellar plica in the knee 
caused by injury, and is this abnormality therefore liable to 
compensation?
Shorter admissions to hospital and more rapid recovery 
after surgery are likely to appeal to patients and hospital 
accountants alike; in the UK, with current concerns about 
the size of waiting lists for routine orthopaedic operations, 
many surgeons will also be tempted to put these techniques 
into practice. In general hospitals it will be important to 
achieve the right balance between general orthopaedic 
surgery and arthroscopy, and it may not be necessary for all 
surgeons to gain and to maintain the necessary experience to 
practise this specialised technique. Clearly the more 
recondite and remarkable procedures described in this book 
will need to be in the hands of surgeons who do little 
else—although, hopefully, they will occasionally take a 
broader view of orthopaedic surgery than that seen through 
their arthroscope.
Clinical Research Unit,
Princess Margaret Rose Orthopaedic Hospital,
Edinburgh EH10 7ED, UK SEAN H U G HES
Cardiovascular Pathology
Edited by R. Virmani, J. B. Atkinson, and J. J. Fenoglio.
Philadelphia: Saunders. 1991. Pp 465. $65/£38. ISBN
0-721632327.
Cardiologists and cardiac surgeons know a fair bit of 
pathology and a great deal of anatomy. As a pathologist 
working at a centre with a large cardiothoracic unit, it can be 
hard work keeping up with one’s clinical colleagues. Help is 
at hand. This excellent book, volume 23 in the Major 
Problems in Pathology series, addresses almost all of the 
current debates in cardiac pathology and will keep the reader 
one jump ahead.
This is a problem-based guide rather than a 
comprehensive textbook of cardiac pathology, with 20
